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Diphtheria toxin (DT)* is the paradigm of the powerful A-B
 
toxins. These bacterial poisons bind to cells, are endocytosed,
and inject their catalytic domain into the cytosol causing
the irreversible modiﬁcation of a key component of the
the host cellular machinery. The mechanism by which the
 
hydrophilic enzymatic fragment of DT crosses the endosomal
membrane and is released into the cytosol remains con-
troversial. In this issue, Ratts et al. (2003) demonstrate
 
that delivery of the DT catalytic domain from the lumen of
puriﬁed early endosomes to the external medium requires
the addition of a cytosolic translocation factor complex
composed in part of Hsp90 and thioredoxin reductase.
 
Diphtheria was the first infectious disease to be studied at
the molecular and cellular level (Pappenheimer, 1993).
Roux and Yersin demonstrated in 1888 that a thermolabile
and protease sensitive “poison” secreted by 
 
Corynebacterium
diphtheriae
 
 was entirely responsible for the fatal disease.
Upon the discovery of toxins, Paul Erlich put forward the
idea that retargeting these proteins, molecules that he named
“magic bullets,” specifically to tumors cells might cure can-
cers. DT is the best studied A-B toxin to date, and was the
first to be retargeted through genetic engineering, and
 
DAB
 
389
 
IL-2 (Ontak
 
®
 
) is the first fusion protein toxin ap-
proved for the treatment of human disease (vanderSpek and
Murphy, 2000). However, the mechanism by which DT
“injects” its enzymatic fragment through the membrane of
early endosomes into the cytosol has indeed remained a
puzzling and controversial problem. In this issue, the group
of John Murphy (Ratts et al., 2003) provides evidence that
the translocation of DT catalytic fragment (DT-C) out of
purified early endosomes is not an autonomous mechanism
performed by the toxin itself, as previously suggested (Oh et
al., 1999), but requires host cellular factors.
DT consists of a catalytic A chain (21 kD) and a B chain
(37 kD), which are linked by a disulfide bridge. The B chain
encompasses both the transmembrane (DT-T) and receptor
binding (DT-R). After binding to its cognate host cell receptor
and endocytosis, the toxin reaches early endosomes, where it
partially unfolds within the low pH of this compartment,
unmasking the hydrophobic helices of DT-T. This allows
membrane insertion of DT-T and translocation of DT-C
into the cytosol. Within the cytosol, DT-C catalyzes the
 
NAD
 
 
 
-dependent ADP-ribosylation of elongation factor 2
(EF-2), thereby stopping protein synthesis and resulting in
cell death (Collier, 2001). Studies performed with artificial
planar lipid bilayers and unilammelar liposomes brought
forward the idea that DT-T domain insertion into lipidic
membranes at low pH is sufficient to allow DT-C to flip
from the cis to the trans side of the leaflet (Oh et al., 1999).
In this model, translocation is performed by the transient
association–dissociation events between the T domain, playing
the role of a transmembrane chaperone and the partially
unfolded hydrophophic molten globule-like DT-C fragment
(Ren et al., 1999). These results led to the notion that the
DT-T domain contains the entire molecular machinery for
mediating the transfer of DT-C across a membrane (Oh et
al., 1999). In this model, DT uses an amazingly simple
system for translocation of a large hydrophilic protein
through lipid membranes.
In their studies, Ratts et al. (2003) took a different approach
to study the DT-C translocation. They made use of an assay
previously described for DT-C translocation across purified
early endosomes (Lemichez et al., 1997), in a study which
also demonstrated the necessity of crude cellular extracts for
productive translocation of DT-C. This assay is based on the
unique ability of DT, as compared with other toxins of this
family, to selectively ADP-ribosylate EF2. By using radio-
 
labeled NAD, concentrations as low as 10
 
 
 
14
 
–10
 
 
 
16
 
 M DT-C
can be detected. In their current study, Ratts et al. (2003)
used DAB
 
389
 
IL-2 instead of DT, a chimeric toxin constructed
by substituting the native receptor-binding domain of DT
with human interleukin-2 (hIL-2) (Ratts and vanderSpek,
2002). DAB
 
389
 
IL-2 shares all the properties of a bona fide
DT except that it binds to high affinity IL-2 receptors with a
K
 
d
 
 similar to that of native IL-2. Using this approach, Ratts
et al. (2003) now report that the in vitro translocation of
DT-C from the lumen of acidified early endosomes into the
cytosol requires a host cell cytosolic translocation factor
(CTF) complex.
The CTF complex was purified from either human T cells
or yeast extracts and found to contain multiple protein
bands ranging in apparent molecular mass from 12 to 100
kD. Identifying individual components of this complex by
mass spectrometry and the use of specific inhibitors, Ratts et
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al. (2003) found that Hsp90 (or its orthologue Hsp82 from
yeast extracts) as well as thioredoxin reductase (TrR-1) were
essential but not sufficient for DT-C translocation. To es-
tablish the functional role of Hsp90 and TrR-1 for DT-C
translocation, the authors conducted a series of immunopre-
cipitation experiments and demonstrated that the removal of
these proteins from the CTF complex prevented DT-C
translocation across endosomal membranes. A role for
Hsp90 as merely a “cofactor” required for DT-C activity
seems to have been excluded since adding Hsp90 back to the
immunodepleted CTF complex did not restore ADP ribosy-
lation activity to the external medium. In addition, using
two inhibitors of Hsp90 geldanamycin and radicicol, and
cis-13-retinoic acid, an inhibitor of TrR-1, Ratts et al.
(2003) were able to show that both factors participate in
DT-C translocation both in vitro and in vivo. These obser-
vations favor a role forHsp90 and/or TrR1 in DT-C mem-
brane translocation. However, to firmly establish that these
proteins are integral components of the CTF complex and
not indirectly acting to maintain the folded conformation of
true components of the CTF, will require the complete re-
constitution of the CTF complex in vitro.
These exciting results have initiated the process of purify-
ing and identifying components of this CTF complex. Once
highly purified, it will be interesting to determine whether
the CTF complex acts directly on the DT-C domain by
“traction” or facilitates its translocation in another manner.
The need of cellular factors for the membrane translocation
of toxin A domains might be a general requirement. For ex-
ample, it is known that the membrane translocation of the
cholera toxin catalytic domain needs the endoplasmic reticu-
lum sec61 pore and chaperones (Tsai et al., 2002).
The earlier observations made through the use of artificial
lipid bilayers led to the conclusion that DT-C domain trans-
location was likely to occur autonomously (Oh et al., 1999);
whereas, using purified early endosomes a host cell CTF
complex appears to be required for this process. These con-
flicting results seem to raise a paradox. However, as indi-
cated by Ratts et al. (2003), both hypotheses might be rec-
onciled in view of earlier observations showing that the
structure of DT upon insertion into lipid bilayers differs de-
pending on whether it is embedded in either cellular or arti-
ficial membranes. It is also important to point out that
the assay used by Ratts et al. does not directly monitor the
DT-C movement across the lipid membrane. However,
Ratts et al., by following the decrease in DT-C enzymatic
activity in the lumen of endosomes and its increase in the ex-
ternal medium, show that a productive membrane transloca-
tion of this molecule has likely occurred.
The possible involvement of Hsp90 in the mechanism of
DT-C membrane translocation might also be an interesting
finding since this protein is different from other chaperones
in that most of its known substrates to date are signal trans-
duction proteins such as steroid hormone receptors and sig-
naling kinases (Young et al., 2001). Very recently, it has
 
been shown that binding of Hsp90 to certain mitochondrial
preproteins is required for their docking to the Tom70 im-
port receptor and their translocation into the inner mem-
brane/matrix (Young et al., 2003). This indicates a new role
for Hsp90 in membrane protein translocation, and may be
related to its detection in the CTF complex.
Following the observations of Ratts et al. (2003), which
provide evidence that cellular factors are required for DT-
C translocation, one is tempted to speculate that this
mechanism may have broader implications. For example,
the Botulinum neurotoxins and 
 
Bacillus anthracis
 
 toxins
are deadly poisons, which might be used for bioterrorism.
These toxins, like DT, are A-B toxins that require passage
through an acidic endosomal compartment to inject their
catalytic fragment into the cytosol. The assay reported by
Ratts et al. (2003) may also allow screening for drugs that
may impair the translocation of DT-C and the catalytic
domain of other toxins into the cytosol. Such an assay may
also allow the screening for pharmaceutical drugs that en-
hance the activity of chimeric toxins by boosting the effi-
ciency of the membrane translocation of their catalytic do-
main resulting in a larger family of targeted “magic
bullets,” thereby more completely fulfilling the dream of
Paul Ehrlich some 100 year ago.
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